Calliditas Therapeutics

About Calliditas Therapeutics

Calliditas Therapeutics (NASDAQ:CALT) is a biopharmaceutical company focused on developing and commercializing novel treatments in areas of significant unmet medical need, with an emphasis on kidney and autoimmune diseases. The company's lead product, Nefecon, is aimed at treating patients with IgA nephropathy, a chronic autoimmune kidney disease. Calliditas Therapeutics has also embarked on several other research and development projects aiming to expand its portfolio and address other serious health conditions. Its objective is to make a significant difference in patients' lives by providing innovative treatments that can manage or potentially cure debilitating diseases. The company’s stock is traded on the NASDAQ under the symbol CALT, enabling investors to take part in its growth and success.

What is Calliditas Therapeutics known for?

Snapshot

2004

Year founded

224

Employees

Stockholm, Sweden

Head office

Loading Map...

Operations

All Locations

Kingdom of Sweden

Products and/or services of Calliditas Therapeutics

Nefecon, an oral formulation targeting IgA Nephropathy (IgAN) to slow kidney function decline.
Setanaxib, a Phase 2b trial for primary biliary cholangitis, a rare liver disease.
Budesonide, an oral suspension for eosinophilic esophagitis to treat inflammation and ease swallowing.
Partnership development for in-licensed products expanding into niche indications with unmet medical needs.
Advanced renal and hepatic disease clinical programs focusing on novel treatments.
Consulting services for drug development, offering expertise in nephrology and immunology.